600488.SHG Tianjin Tianyao Pharmaceuticals Co Ltd
- Market cap
- CNY 5.47B
- P/E
- 125.3x
- P/B
- 1.74x
- ROE
- 2.0%
- Dividend yield
- 2.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600488.SHG undervalued?
Graham numberThe Graham number of Tianjin Tianyao Pharmaceuticals Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Tianyao Pharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Tianjin Tianyao Pharmaceuticals Co Ltd yet.
Tianjin Tianyao Pharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, betamethasone product series, and other hormone precursors. The company provides amino acid raw materials, as well as preparations, including injec…
Full company profileTianjin Tianyao Pharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Tianyao Pharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.69B | 1.97B | 2.43B | 3.33B | 3.12B | 3.75B | 3.69B | 3.78B | 3.22B | 2.91B | 2.49B |
| Gross Profit | 496M | 697M | 1.19B | 1.59B | 1.38B | 1.73B | 1.76B | 1.70B | 1.42B | 1.19B | 960M |
| Operating Income | 151M | 188M | 222M | 281M | 132M | 146M | 70.2M | 169M | 226M | 302M | 197M |
| EBITDA | 262M | 299M | 368M | 489M | 339M | 403M | 319M | 476M | 545M | 438M | 129M |
| Net Income | 97.7M | 130M | 145M | 162M | 34.0M | 48.7M | 35.4M | 117M | 133M | 70.6M | 60.9M |
| EPS | 0.09 | 0.12 | 0.13 | 0.15 | 0.03 | 0.05 | 0.03 | 0.11 | 0.12 | 0.06 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 3.00B | 4.28B | 4.80B | 5.28B | 6.18B | 6.35B | 6.65B | 6.14B | 5.70B | 5.76B | 5.56B |
| Total Liabilities | 511M | 1.15B | 1.52B | 1.70B | 2.40B | 2.53B | 2.90B | 2.39B | 1.81B | 1.86B | 1.70B |
| Shareholders' Equity | 2.47B | 2.72B | 2.84B | 2.92B | 2.99B | 2.99B | 2.97B | 2.95B | 3.06B | 3.03B | 3.03B |
| Cash & Short-term Investments | 569M | 480M | 338M | 246M | 244M | 232M | 648M | 719M | 638M | 825M | 719M |
| Total Debt | 385M | 385M | 777M | 890M | 1.23B | 1.41B | 1.40B | 547M | 533M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 63.3M | -8.15M | 189M | 279M | 347M | 317M | 654M | 783M | 569M | 136M | - |
| Capital Expenditure | 64.8M | 121M | 204M | 279M | 459M | 371M | 202M | 133M | 77.7M | 55.9M | 37.4M |
| Free Cash Flow | -1.46M | -129M | -14.3M | 325K | -112M | -54.0M | 451M | 650M | 492M | 80.6M | 362M |
| Ratios | |||||||||||
| ROE | 4.0% | 4.8% | 5.1% | 5.5% | 1.1% | 1.6% | 1.2% | 4.0% | 4.4% | 2.3% | 2.0% |
| ROA | 3.3% | 3.0% | 3.0% | 3.1% | 0.6% | 0.8% | 0.5% | 1.9% | 2.3% | 1.2% | 1.1% |
| Net Profit Margin | 5.8% | 6.6% | 6.0% | 4.9% | 1.1% | 1.3% | 1.0% | 3.1% | 4.2% | 2.4% | 2.5% |
| Debt to Equity | 0.16x | 0.14x | 0.27x | 0.30x | 0.41x | 0.47x | 0.47x | 0.19x | 0.17x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianjin Tianyao Pharmaceuticals Co Ltd dividends
- Dividend yield
- 2.32%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 180.0%
- Ex-dividend date
- Jul 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 127M | 0.12 | 180.0% |
| 2024 | CNY 123M | 0.11 | 92.4% |
| 2023 | CNY 10.9M | 0.01 | 9.3% |
| 2022 | CNY 15.3M | 0.01 | 43.2% |
| 2021 | CNY 11.0M | 0.01 | 22.6% |
| 2020 | CNY 43.7M | 0.04 | 128.5% |
| 2019 | CNY 71.3M | 0.07 | 44.1% |
| 2018 | CNY 70.9M | 0.06 | 48.8% |
| 2017 | CNY 30.5M | 0.03 | 23.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Mar 13, 2013.
Who owns Tianjin Tianyao Pharmaceuticals Co Ltd
- Insiders 57.68%
- Institutions 0.87%
- Public & others 41.45%
- Shares outstanding 1.09B
- Free float 473M
Tianjin Tianyao Pharmaceuticals Co Ltd company profile
- Company name
- Tianjin Tianyao Pharmaceuticals Co Ltd
- Ticker
- 600488.SHG
- ISIN
- CNE000001840
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 24, 2001
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,731
- Fiscal year end
- December
- Address
- No. 221 Huanghai Road, Tianjin, China, 300457
- Phone
- 86 22 6074 0048
- Website
- tjpcty.com
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, betamethasone product series, and other hormone precursors. The company provides amino acid raw materials, as well as preparations, including injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, and tablets. It also exports its products to the United States, Southeast Asia, Asia, Europe, South America, Africa, and internationally. The company was founded in 1939 and is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. operates as a subsidiary of Tianjin Pharmaceutical Group Co., Ltd.
Tianjin Tianyao Pharmaceuticals Co Ltd management
5- Mr. Shuxiang LiGM & Director · born 1972
- Mr. Liyan ZhuCFO & Director · born 1981
- Mr. Hao LiuDeputy GM & Director · born 1983
- Mr. Bo LiuBoard of Directors Secretary · born 1985
- Mr. Jie ZhangDeputy General Manager · born 1980